3137-56-2

Usage

Property

Chemical compound

Physical state

Yellow crystalline solid

Molecular weight

173.53 g/mol

Primary use

Building block in the production of pharmaceuticals

Applications

Antiparasitic, antibacterial drugs, herbicides, pesticides

Stability

Stable under normal conditions

Hazard level

Not considered highly hazardous when handled and stored properly

Upstream product

• 2164-83-2 4,6-Dihydroxy-5-nitro-pyrimidine 
• 4765-77-9 4-chloro-6-hydroxypyrimidine 

Downstream Products

• 16206-22-7 1,2,5-Oxadiazolo<3.4-d>pyrimidin-7(6H)-on-1-oxid 
• 78555-90-5 5-Nitro-6-(N'-phenyl-hydrazino)-3H-pyrimidin-4-one 
• 118974-80-4 6-<(4-methoxybenzyl)(2-oxo-2-phenylethyl)amino>-5-nitro-4(3H)-pyrimidinone 
• 3137-60-8 5-amino-4-chloro-6-hydroxypyrimidine 
• 4316-93-2 4,6-dichloro-5-nitropyrimidine 

Relevant academic research and scientific papers

Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of Cryptococcus neoformans and Cryptococcus gattii

Opportunistic infections from pathogenic fungi present a major challenge to healthcare because of a very limited arsenal of antifungal drugs, an increasing population of immunosuppressed patients, and increased prevalence of resistant clinical strains due to overuse of the few available antifungals. Cryptococcal meningitis is a life-threatening opportunistic fungal infection caused by one of two species in the Cryptococcus genus, Cryptococcus neoformans and Cryptococcus gattii. Eighty percent of cryptococcosis diseases are caused by C. neoformans that is endemic in the environment. The standard of care is limited to old antifungals, and under a high standard of care, mortality remains between 10 and 30%. We have identified a series of 5-nitro-6-thiocyanatopyrimidine antifungal drug candidates using in vitro and computational machine learning approaches. These compounds can inhibit C. neoformans growth at submicromolar levels, are effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and are not antagonistic with currently approved antifungals.

Design, synthesis, and anticancer evaluation of acetamide and hydrazine analogues of pyrimidine

A library of acetamide and hydrazine analogues were generated on the pyrimidine ring through a multistep reaction starting from 5-nitro-pyrimidine-4,6-diol and pyrimidine-4,6-diol, respectively. The synthesized analogues were screened for in vitro cytotoxic activity against various human cancer cell lines like HCT-1 and HT-15 (colon), MCF-7(breast), PC-3 (prostrate), SF268 (CNS) using MTT method. From the bioassay results, it was observed that even though many of the synthesized derivatives exhibited a good potency against various screened cancer cell lines, compound 14a from the acetamide series was found to show potent anticancer activity on all the tested cancer cell lines with IC50 value of 0.36μM on CNS cell line and 1.6μM on HT-21 cell line, and compound 19xxi from hydrazine series of pyrimidine showed potent activity against three tested cancer cell lines with IC50 value of 0.76μM on HT-29 cell line, 2.6μM on HCT-15, and 3.2μM on MCF-7 cell line.